Tredje AP fonden Sells 1,683 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Tredje AP fonden lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 50.0% in the fourth quarter, Holdings Channel reports. The firm owned 1,684 shares of the medical research company’s stock after selling 1,683 shares during the period. Tredje AP fonden’s holdings in Bio-Rad Laboratories were worth $553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of BIO. Wealthfront Advisers LLC purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $342,686,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Bio-Rad Laboratories by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after buying an additional 4,260 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Bio-Rad Laboratories by 3.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after buying an additional 9,584 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at $83,681,000. Finally, Mawer Investment Management Ltd. lifted its position in shares of Bio-Rad Laboratories by 63.0% during the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after buying an additional 84,237 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BIO. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Wells Fargo & Company lowered their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Price Performance

Shares of BIO stock opened at $255.34 on Friday. The firm has a market cap of $7.15 billion, a P/E ratio of -3.93 and a beta of 0.99. Bio-Rad Laboratories, Inc. has a fifty-two week low of $244.00 and a fifty-two week high of $387.99. The business’s 50 day moving average price is $311.97 and its 200-day moving average price is $328.01. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.